Ed Mathers
InvestorPartner at New Enterprise Associates (NEA)
Maryland
Writes $2M – $50M checks · typically $25M
FoundedAffinia TherapeuticsAkouosCurzion Pharmaceuticals IncEnvisia TherapeuticsOnkure Therapeutics IncRhythm Pharmaceuticals
About
Ed Mathers is a Partner on NEA's healthcare team, where he has worked since 2008, focusing on biotechnology and specialty pharmaceuticals investments. Before NEA, he was EVP of Corporate Development and Venture at MedImmune, contributing to its 2007 sale to AstraZeneca, and previously held roles at Inhale Therapeutic Systems and Glaxo Wellcome (now GSK). His investment interests include gene therapy, nonviral gene therapy, RNA editing, and immunology and inflammation.
Invests in
Biotech
Experience
- New Enterprise AssociatesPartnercurrent2008 — present
- New Enterprise AssociatesPartnercurrent2008 — present
- MedImmuneExec VP Corporate Development and Venture2002 — 2008
- GlaxoVP1985 — 1999
Education
- NC State UniversityBachelor of Science (BS), Chemistry1978 — 1982
Deals · 6
Curzion Pharmaceuticals IncBoard seat
via New Enterprise Associates (NEA) · filed Jul 2019 · $3.5M raise
Mirum PharmaceuticalsBoard seat
via New Enterprise Associates (NEA) · filed Nov 2018 · $120.1M raise
Senti BiosciencesBoard seat
via New Enterprise Associates (NEA) · filed Feb 2018 · $53.4M raise
AkouosBoard seat
via New Enterprise Associates (NEA) · filed Nov 2017 · $7.6M raise
SynlogicBoard seat
via New Enterprise Associates (NEA) · filed Feb 2016 · $40.6M raise
Envisia TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Oct 2015 · $5.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at New Enterprise Associates (NEA)
Network11
Investors connected to Ed in public investor directories — a warm-intro map.